The Effect of Chemotherapy Hormesis on Ovarian Cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K23884
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0901:Oncology and related fields
• Research Institution: Nagoya University
• Principal Investigator: Tamauchi Satoshi 名古屋大学, 医学部附属病院, 病院助教 (50845097)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Keywords: 卵巣癌 / 抗癌剤 / ホルミシス / 低酸素 / 微小環境

Outline of Final Research Achievements

The purpose of this study was to examine the hypothesis that the bias in the amount of oxygen and anticancer drugs delivered to the tumor due to differences in the microenvironment may in fact promote cancer growth.
Results] Cell proliferation of NOS3 was significantly enhanced by administration of CDDP at doses 1/10 to 1/100 of IC50. The increase in cell proliferation in this concentration range was more pronounced in 1% oxygen culture than in 20% oxygen culture. Metabolome analysis showed that reduced glutathione and total glutathione, which are believed to have protective effects against anticancer drugs, were increased in cells treated with 1/100 dose of IC50.

Free Research Field

婦人科悪性腫瘍

Academic Significance and Societal Importance of the Research Achievements

低濃度の抗癌剤投与は、かえって癌細胞の増殖を亢進させ (抗癌剤ホルミシス)、低酸素状態によってこの作用が増強することが判明した。卵巣癌の腹膜微小環境においては、酸素や抗癌剤のデリバリーに不均衡が生じることは十分あり得、抗癌剤ホルミシスを念頭において治療に当たる必要があると考えられる。